Amurensin G inhibits angiogenesis and tumor growth of tamoxifen-resistant breast cancer via Pin1 inhibition

Food and Chemical Toxicology

Volumn 50, Issue 10, 2012, Pages 3625-3634

  Kim, Jung Ae ^a   Kim, Mi Ra ^b   Kim, Ok ^c   Phuong, Nguyen Thi Thuy ^b,c   Yoon, Jieun ^d   Oh, Won Keun ^c   Bae, KiHwan ^e   Kang, Keon Wook ^b  

^a Yeungnam University   (South Korea)

^b Seoul National University   (South Korea)

^c Chosun University   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^e Chungnam National University   (South Korea)

Author keywords

Amurensin G; Angiogenesis; Pin1; Tamoxifen resistant breast cancer; VEGF; Vitis amurensis

Indexed keywords

AMPELOPSIN A; AMPELOPSIN F; AMURENSIN G; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PEPTIDYLPROLYL ISOMERASE PIN1; PHOSPHATIDYLINOSITOL 3 KINASE; PICEATANNOL; RESVERATROL; STILBENE DERIVATIVE; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; VASCULOTROPIN; VINIFERIN;

ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CELL NUCLEUS; CELL STRAIN MCF 7; CHICK; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOWN REGULATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYPOXIA RESPONSIVE ELEMENT; INHIBITION KINETICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION; VITIS; VITIS AMURENSIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIBENZOCYCLOHEPTENES; DRUG RESISTANCE, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDYLPROLYL ISOMERASE; RESORCINOLS; TAMOXIFEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

VITACEAE; VITIS AMURENSIS;

EID: 84865975577     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.07.027     Document Type: Article

References (52)

1. Auerbach R., Kubai L., Knighton D., Folkman J. A simple procedure for the long-term cultivation of chicken embryos. Dev. Biol. 1974, 41:391-394.
2. Bao L., Sauter G., Sowadski J., Lu K.P., Wang D. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am. J. Pathol. 2004, 164:1727-1737.
3. Bayer E., Goettsch S., Mueller J.W., Griewel B., Guiberman E., Mayr L.M., Bayer P. Structural analysis of the mitotic regulator hPin1 in solution: insights into domain architecture and substrate binding. J. Biol. Chem. 2003, 278:26183-26193.
4. Bracken A.P., Ciro M., Cocito A., Helin K. E2F target genes: unraveling the biology. Trends Biochem. Sci. 2004, 29:409-417.
5. Brakenhielm E., Cao R., Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 2001, 15:1798-1800.
6. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000, 6:389-395.
7. Chao S.H., Greenleaf A.L., Price D.H. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription. Nucleic Acids Res. 2001, 29:767-773.
8. Choi H.K., Yang J.W., Roh S.H., Han C.Y., Kang K.W. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr. Relat. Cancer 2007, 14:293-303.
9. Clemons M., Danson S., Howell A. Tamoxifen ('Nolvadex'): a review. Cancer Treat. Rev. 2002, 28:165-180.
10. Dorai T., Aggarwal B.B. Role of chemopreventive agents in cancer therapy. Cancer Lett. 2004, 215:129-140.
11. Duncan K.E., Dempsey B.R., Killip L.E., Adams J., Bailey M.L., Lajoie G.A., Litchfield D.W., Brandl C.J., Shaw G.S., Shilton B.H. Discovery and characterization of a nonphosphorylated cyclic peptide inhibitor of the peptidylprolyl isomerase, Pin1. J. Med. Chem. 2011, 54:3854-3865.
12. El-Azab M., Hishe H., Moustafa Y., El-Awady el.-S. Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice. Eur. J. Pharmacol. 2011, 652:7-14.
13. Gusman J., Malonne H., Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 2001, 22:1111-1117.
14. Ha T.D., Chen Q.C., Hung T.M., Youn U.J., Ngoc T.M., Thuong P.T., Kim H.J., Seong Y.H., Min B.S., Bae K. Stilbenes and oligostilbenes from leaf and stem of Vitis amurensis and their cytotoxic activity. Arch. Pharm. Res. 2009, 32:177-183.
15. Huang K.S., Lin M., Cheng G.F. Anti-inflammatory tetramers of resveratrol from the roots of Vitis amurensis and the conformations of the seven-membered ring in some oligostilbenes. Phytochemistry 2001, 58:357-362.
16. Igata M., Motoshima H., Tsuruzoe K., Kojima K., Matsumura T., Kondo T., Taguchi T., Nakamaru K., Yano M., Kukidome D., Matsumoto K., Toyonaga T., Asano T., Nishikawa T., Araki E. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ. Res. 2005, 97:837-844.
17. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics. Cancer J. Clin. 2008, 58:71-96.
18. Kim M.R., Choi H.S., Heo T.H., Hwang S.W., Kang K.W. Induction of vascular endothelial growth factor by peptidyl-prolyl isomerase Pin1 in breast cancer cells. Biochem. Biophys. Res. Commun. 2008, 369:547-553.
19. Kim M.R., Choi H.S., Yang J.W., Park B.C., Kim J.A., Kang K.W. Enhancement of vascular endothelial growth factor-mediated angiogenesis in tamoxifen-resistant breast cancer cells: role of Pin1 overexpression. Mol. Cancer Ther. 2009, 8:2163-2171.
20. Kim M.R., Choi H.K., Cho K.B., Kim H.S., Kang K.W. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci. 2009, 100:1834-1841.
21. Kimura Y., Okuda H. Resveratrol isolated from polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in lewis lung carcinoma-bearing mice. J. Nutr. 2001, 131:1844-1849.
22. Knowlden J.M., Hutcheson I.R., Jones H.E., Madden T., Gee J.M., Harper M.E., Barrow D., Wakeling A.E., Nicholson R.I. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044.
23. Kundu J.K., Surh Y.J. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 2008, 269:243-261.
24. Lee C.W., Sørensen T.S., Shikama N., La Thangue N.B. Functional interplay between p53 and E2F through co-activator p300. Oncogene 1998, 16:2695-2710.
25. Lee K.Y., Lee J.W., Nam H.J., Shim J.H., Song Y., Kang K.W. PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cells. Mol. Cells 2011, 32:107-111.
26. Lu K.P. Pinning down cell signaling, cancer and Alzheimer's disease. Trends Biochem. Sci. 2004, 29:200-209.
27. Marson L.P., Kurian K.M., Miller W.R., Dixon J.M. The effect of tamoxifen on breast tumour vascularity. Breast Cancer Res. Treat. 2001, 66:9-15.
28. Monje P., Hernandez-Losa J., Lyons R.J., Castellone M.D., Gutkind J.S. Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J. Biol. Chem. 2005, 280:35081-35084.
29. Mueller S.O., Clark J.A., Myers P.H., Korach K.S. Mammary gland development in adult mice requires epithelial and stromal estrogen receptor alpha. Endocrinology 2002, 143:2357-2365.
30. Oak M.H., El-Bedoui J., Schini-Kerth V.B. Antiangiogenic properties of natural polyphenols from red wine and green tea. J. Nutr. Biochem. 2005, 16:1-8.
31. Oh W.K., Cho K.B., Hien T.T., Kim T.H., Kim H.S., Dao T.T., Han H.K., Kwon S.M., Ahn S.G., Yoon J.H., Kim T.H., Kim Y.G., Kang K.W. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Mol. Pharmacol. 2010, 78:855-864.
32. Petrangeli E., Lubrano C., Ortolani F., Ravenna L., Vacca A., Sciacchitano S., Frati L., Gulino A. Estrogen receptors: new perspectives in breast cancer management. J. Steroid Biochem. Mol. Biol. 1994, 49:327-331.
33. Pulikkan J.A., Dengler V., Peer Zada A.A., Kawasaki A., Geletu M., Pasalic Z., Bohlander S.K., Ryo A., Tenen D.G., Behre G. Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML. Leukemia 2010, 24:914-923.
34. Ren B., Cam H., Takahashi Y., Volkert T., Terragni J., Young R.A., Dynlacht B.D. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 2002, 16:245-256.
35. Ribatti D., Vacca A. Models for studying angiogenesis in vivo. Int. J. Biol. Markers 1999, 14:207-213.
36. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
37. Rose C., Thorpe S.M., Andersen K.W., Pedersen B.V., Mouridsen H.T., Blichert-Toft M., Rasmussen B.B. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985, 1:16-19.
38. Ryo A., Liou Y.C., Wulf G., Nakamura M., Lee S.W., Lu K.P. PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol. Cell. Biol. 2002, 22:5281-5295.
39. Ryo A., Liou Y.C., Lu K.P., Wulf G. Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. J. Cell Sci. 2003, 116:773-783.
40. Ryo A., Uemura H., Ishiguro H., Saitoh T., Yamaguchi A., Perrem K., Kubota Y., Lu K.P., Aoki I. Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer. Clin. Cancer Res. 2005, 15:7523-7531.
41. Savouret J.F., Quesne M. Resveratrol and cancer: a review. Biomed. Pharmacother. 2002, 56:84-87.
42. Schlachterman A., Valle F., Wall K.M., Azios N.G., Castillo L., Morell L., Washington A.V., Cubano L.A., Dharmawardhane S.F. Combined resveratrol, quercetin, and catechin treatment reduces breast tumor growth in a nude mouse model. Transl. Oncol. 2008, 1:19-27.
43. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 2000, 35:71-103.
44. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 2002, 8:S62-S67.
45. Tonetti D.A., Chisamore M.J., Grdina W., Schurz H., Jordan V.C. Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br. J. Cancer 2000, 83:782-791.
46. Tseng S.H., Lin S.M., Chen J.C., Su Y.H., Huang H.Y., Chen C.K., Lin P.Y., Chen Y. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin. Cancer Res. 2004, 10:2190-2202.
47. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32:1377-1382.
48. Wenzel E., Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 2005, 49:472-481.
49. Wulf G.M., Ryo A., Wulf G.G., Lee S.W., Niu T., Petkova V., Lu K.P. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 2001, 20:3459-3472.
50. Xie K., Wei D., Shi Q., Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 2004, 15:297-324.
51. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
52. You H., Zheng H., Murray S.A., Yu Q., Uchida T., Fan D., Xiao Z.X. IGF-1 induces Pin1 expression in promoting cell cycle S-phase entry. J. Cell. Biochem. 2002, 84:211-216.